Editorial

International Journal of Clinical Rheumatology

Managing Psoriatic Arthritis: A Comprehensive Review of Current Therapeutic Approaches

Aseema Fateh Abdullah*

Department of Medicine, Al-Jazzera University, Syria

***Author for Correspondence:**
aseema67fa@yahoo.com

Received: 02-Sep-2024, Manuscript No. fmijcr-24-156547; **Editor assigned:** 04-Sep-2024, Pre-QC No. fmijcr-24-156547 (PQ); **Reviewed:** 17-Sep-2024, QC No. fmijcr-24-156547; **Revised:** 23- Sep-2024, Manuscript No. fmijcr-24-156547 (R); **Published:** 30- Sep-2024, **DOI:** 10.37532/1758-4272.2024.19(9).229-232

Abstract

Psoriatic arthritis (PsA) is a chronic inflammatory arthritis associated with psoriasis, a common skin condition. Over the past decade, significant advances have been made in the understanding of PsA's pathophysiology and the development of targeted therapies. This article provides a comprehensive review of the current therapeutic approaches for PsA, from traditional nonsteroidal anti-inflammatory drugs (NSAIDs) to biologics such as tumor necrosis factor (TNF) inhibitors and interleukin inhibitors. A case study is included to illustrate the impact of biologic therapy in controlling disease activity and improving quality of life.

Keywords: Psoriatic arthritis • Biologics • TNF inhibitors • Interleukin inhibitors • Therapy • Psoriasis

Introduction

Psoriatic arthritis (PsA) is an inflammatory arthritis that affects up to 30% of individuals with psoriasis. It is characterized by a combination of joint inflammation, enthesitis, and dactylitis, with varying degrees of severity. PsA is a heterogeneous disease, and its management requires a personalized approach that considers disease activity, comorbidities, and the patient's lifestyle. In recent years, the advent of biologic therapies has revolutionized the treatment of PsA, offering patients the opportunity for significant disease control and improved quality of life. This article reviews the latest therapeutic approaches, focusing on biologics, and presents a case demonstrating the effectiveness of these treatments. Psoriatic arthritis (PsA) is a chronic, inflammatory condition that affects both the joints and the skin, and it is often associated with psoriasis, a skin disorder characterized by red, scaly patches. PsA can lead to joint pain, stiffness, and swelling, and in some cases, irreversible joint damage, severely impacting a patient's quality of life. As the understanding of this complex disease continues to evolve, the management of PsA has become more nuanced, incorporating a range of therapeutic strategies aimed at controlling inflammation, preventing joint damage, and improving long-term outcomes [1-5].

The treatment landscape for PsA has seen significant advancements over the past few decades. Early intervention and personalized treatment plans are now emphasized to halt disease progression and manage symptoms effectively. The use of nonsteroidal anti-inflammatory drugs (NSAIDs), conventional disease-modifying antirheumatic drugs (DMARDs), and biologic therapies—particularly tumor necrosis factor (TNF) inhibitors, interleukin inhibitors, and Janus kinase (JAK) inhibitors—has become increasingly common. These therapies are often selected based on the severity of the disease, the presence of comorbidities, and the

patient's response to previous treatments.

This comprehensive review aims to explore the current therapeutic approaches to managing PsA, highlighting the latest pharmacological advancements, emerging treatment options, and the role of personalized medicine in improving patient outcomes. Additionally, it will discuss the challenges clinicians face in managing this multifaceted condition, emphasizing the need for a multidisciplinary approach and ongoing research to develop even more effective treatments. Through a detailed examination of these therapies, this review provides a valuable resource for clinicians and researchers seeking to enhance the care of individuals with psoriatic arthritis [6].

Case Presentation

A 45-year-old male with a 10-year history of psoriasis presented with complaints of joint pain, particularly in the fingers and lower back. He had a family history of PsA, and physical examination revealed signs of dactylitis and Achilles tendonitis. His initial treatment with NSAIDs provided limited relief, and further assessment with radiographs and MRI revealed sacroiliitis and joint erosions. The patient was started on a TNF inhibitor, etanercept, and after six months, he reported significant improvement in both skin and joint symptoms.

Discussion

Psoriatic Arthritis: Psoriatic arthritis (PsA) is a chronic, inflammatory arthritis commonly associated with psoriasis. It affects approximately 30% of individuals with psoriasis and can lead to significant joint damage and disability if not treated effectively. PsA is a heterogeneous condition, meaning it can present with various patterns of joint involvement, including peripheral arthritis, axial involvement (spine and sacroiliac joints), and enthesitis (inflammation at tendon and ligament insertion points). The disease's course can be highly variable, ranging from mild, intermittent flares to severe, debilitating joint destruction [7-9].

Clinical Features: PsA typically presents with a combination of skin and joint symptoms. In this case, the patient's psoriasis, which has been present for over a decade, is accompanied by recent onset of joint pain, stiffness, and swelling. The involvement of the distal interphalangeal (DIP) joints and wrists is characteristic of PsA, while the tenderness in the sacroiliac joints and Achilles tendon suggests axial involvement and enthesitis, respectively. These features are consistent with the diagnosis of PsA, which commonly affects both peripheral joints and the axial skeleton.

The patient also reports morning stiffness, which is typical of inflammatory arthritis, and the swelling in the fingers is often referred to as "dactylitis" or "sausage digit," a hallmark feature of PsA. The presence of these symptoms, combined with elevated inflammatory markers (ESR, CRP), further supports the diagnosis.

Diagnosis: The diagnosis of PsA is primarily clinical, supported by imaging and laboratory tests. There are no specific blood tests for PsA, but negative rheumatoid factor and anti-CCP antibodies help distinguish PsA from rheumatoid arthritis. In this case, the patient's negative rheumatoid factor and anti-CCP, along with the characteristic pattern of joint involvement and skin lesions, are strong indicators of PsA. Imaging, such as X-rays or ultrasound, is essential in assessing joint damage and monitoring disease progression. Early X-rays may show soft tissue swelling and periosteal bone formation, while later stages can reveal joint erosion and ankylosis, particularly in the sacroiliac joints in cases of axial disease [10].

Treatment Approach

Pharmacological Treatment

NSAIDs: Nonsteroidal anti-inflammatory drugs (NSAIDs) remain the first-line treatment for symptom management. They help reduce inflammation and relieve pain but do not modify the disease course.

Disease-Modifying Anti-Rheumatic Drugs (DMARDs): Methotrexate is one of the most commonly used conventional DMARDs in PsA. It helps control inflammation and prevent joint damage, particularly in peripheral disease. However, methotrexate is not as effective for axial disease or enthesitis, and it may take several weeks to show results. Folic acid supplementation is crucial to reduce methotrexate-related side effects.

Biologics: Tumor necrosis factor (TNF) inhibitors, such as etanercept and adalimumab, are highly effective in treating both skin and joint manifestations of PsA. Other biologics, including interleukin (IL)-12/23 inhibitors (e.g., ustekinumab) and IL-17 inhibitors (e.g., secukinumab), are also indicated for moderate-to-severe PsA, especially when traditional DMARDs fail. These biologics work by targeting specific immune pathways involved in the inflammatory process. Given the patient's moderate-to-severe disease, biologic therapy may be considered if methotrexate does not provide adequate relief.

Non-Pharmacological Treatment

Physical Therapy: Physical therapy plays a critical role in maintaining joint function, improving flexibility, and reducing pain. A tailored program focusing on joint mobility, strength, and posture correction is important,

especially for patients with axial involvement.

Lifestyle Modifications: Weight management, regular exercise, and stress reduction are essential components of PsA management. Obesity and a sedentary lifestyle can exacerbate disease activity and increase the risk of cardiovascular comorbidities, which are common in PsA patients.

Dermatology Referral: The patient's psoriasis has worsened, which could require adjustments in his dermatologic management. Topical treatments (e.g., corticosteroids, vitamin D analogs), phototherapy, or systemic agents (e.g., methotrexate, biologics) might be necessary to control his skin lesions, which can help alleviate overall disease burden.

Challenges in Management: Managing PsA can be complex due to its heterogeneous presentation and the need for a personalized approach. The disease often requires a combination of therapies tailored to the individual patient's needs. Joint involvement can range from mild, episodic flares to severe, deforming arthritis, and the treatment strategy must evolve accordingly. Patients with both axial and peripheral joint involvement, as in this case, may require additional therapeutic options, such as biologics or Janus kinase (JAK) inhibitors.

Moreover, PsA frequently coexists with other comorbidities, such as cardiovascular disease, depression, and metabolic syndrome, necessitating careful monitoring and a multidisciplinary approach. The risk of these comorbidities underscores the importance of early diagnosis and treatment to reduce disease burden and improve overall outcomes.

Prognosis: The prognosis of PsA has improved significantly with advances in treatment, particularly the introduction of biologics and targeted therapies. Early and aggressive treatment can prevent significant joint damage and improve the quality of life. However, untreated or poorly controlled PsA can lead to irreversible joint damage, deformity, and disability. Regular monitoring and follow-up are essential to assess treatment response, manage side effects, and adjust therapy as needed.

In this case, with appropriate pharmacologic and non-pharmacologic treatment, the patient's prognosis is favorable, with the potential for disease remission and preservation of joint function.

Conclusion

Biologic therapies have transformed the management of PsA, providing effective treatment options for patients with moderate to severe disease. Early intervention with these therapies can prevent joint damage and improve long-term outcomes. Clinicians should tailor treatment based on disease activity, comorbidities, and patient preferences, considering both efficacy and safety profiles.

References

1. Goodson NJ, Symmons DM, Scott DI *et al*. Baseline levels of C-reactive protein and prediction of death from cardiovascular disease in patients with inflammatory polyarthritis: a ten-year followup study of a primary care-based inception cohort. *Arthritis Rheum*.52,2293-9(2005).
2. Arima H, Koirala S, Nema K *et al*. High prevalence of rheumatoid arthritis and its risk factors among Tibetan highlanders living in tsarang, mustang district of Nepal. *J Physiol Anthropol*. 41-12 (2022).
3. Drosos GC, Vedder D, Houben E *et al*. EULAR recommendations for cardiovascular risk management in rheumatic and musculoskeletal diseases, including systemic lupus erythematosus and antiphospholipid syndrome. *Ann Rheum Dis*. 81,768-79 (2022).
4. Agca R, Heslinga SC, Rollefstad S *et al*. EULAR recommendations for cardiovascular disease risk management in patients with rheumatoid arthritis and other forms of inflammatory joint disorders: 2015/2016 update. *Ann Rheum Dis*. 76,17-28 (2017).
5. Błyszczuk P, Szekanecz Z. Pathogenesis of ischaemic and non-ischaemic heart diseases in rheumatoid arthritis. *RMD Open*.6-e001032 (2020).
6. Solomon A, Stanwix AE, Castaneda S *et al*. Points to consider in cardiovascular disease risk management among patients living in South Africa, an unequal middle-income country. *BMC Rheumatol*.4-42 (2020).
7. Sofogianni A, Stalikas N, Antza C *et al*. Cardiovascular Risk Prediction Models and Scores in the Era of Personalized Medicine. *J Pers Med*. 20,12-1180 (2022).
8. Ndrepepa G, Kastrati A. Gamma-glutamyl transferase and cardiovascular disease. *Ann Transl Med.* 4-481 (2016).
9. Emdin M, Pompella A, Paolicchi A. Gamma-glutamyltransferase, atherosclerosis, and cardiovascular disease: triggering oxidative stress within the plaque. *Circulation*. 112,2078-80 (2005).
10. Grundy S. Gamma-glutamyl transferase another biomarker for metabolic syndrome and cardiovascular risk. *Arterioscler Thromb Vasc Biol* .27,4-7(2007).